10:03 AM EST - Aptose Biosciences Inc. : Announced that it received a response from the U.S. Food and Drug Administration (FDA) regarding the clinical hold of Aptose’s Phase 1b clinical trial of APTO-253 in patients with hematologic cancers requesting additional information and informing Aptose that the hold would not be removed until this information is submitted and reviewed. Aptose Biosciences Inc.
shares T.APS are trading down $0.59 at $3.11.
